Detalhe da pesquisa
1.
The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD.
Eur Respir J
; 59(4)2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34503985
2.
Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator.
Respir Res
; 21(Suppl 1): 102, 2020 Sep 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32907566
3.
Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies.
Respir Res
; 21(Suppl 1): 212, 2020 Sep 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32907575
4.
A Randomized Trial of Dual-Acting Bronchodilator AZD8871 for Chronic Obstructive Pulmonary Disease.
Am J Respir Crit Care Med
; 199(10): 1282-1284, 2019 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30768909
5.
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability After Subcutaneous Administration of Tozorakimab in Healthy Chinese Participants.
Clin Pharmacol Drug Dev
; 2024 Mar 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38523487
6.
A Randomized Phase I Study of the Anti-Interleukin-33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease.
Clin Pharmacol Ther
; 115(3): 565-575, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38115209
7.
AZD9567 versus prednisolone in patients with active rheumatoid arthritis: A phase IIa, randomized, double-blind, efficacy, and safety study.
Clin Transl Sci
; 16(12): 2494-2506, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37873558
8.
Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists.
Int J Chron Obstruct Pulmon Dis
; 17: 1715-1733, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35941901
9.
Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany.
Clin Drug Investig
; 42(4): 319-331, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35290649
10.
A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink.
Int J Chron Obstruct Pulmon Dis
; 16: 1461-1475, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34103906
11.
Use of aclidinium did not increase the risk of death in a noninterventional cohort study in the Clinical Practice Research Datalink (CPRD), United Kingdom.
Respir Med
; 152: 37-43, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31128608
12.
A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease.
Respir Med
; 125: 39-48, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28340861
13.
Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD.
Respir Med
; 116: 41-8, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27296819